Overview

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

Open-label, interventional, multi-centre, randomized phase II study. Cancer studied is non-metastatic muscle invasive bladder cancer (MIBC). Avelumab administered every 2 weeks is used as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers in combination with standard chemotherapy or alone.

Phase:

Phase 2

Details

Lead Sponsor:

Jules Bordet Institute

Collaborators:

Merck KGaA, Darmstadt, Germany
Merck Sharp & Dohme Corp.

Treatments:

Antibodies, Monoclonal
Avelumab